Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) plus vemurafenib (V) in the phase Ill IMspire150 study.

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPASCIERTO, Paolo AntonioROBERT, CarolineLEWIS, Karl D.MUNHOZ, RodrigoLISZKAY, GabriellaMERINO, Luis de la CruzOLAH, JuditQUEIROLO, PaolaMACKIEWICZ, JacekLI, HaochengZHU, QianMCNALLY, V.MCKENNA, Edward FrancisGUTZMER, RalfMCARTHUR, Grant A.2021-01-252021-01-252020JOURNAL OF CLINICAL ONCOLOGY, v.38, n.15, suppl.S, 20200732-183Xhttps://observatorio.fm.usp.br/handle/OPI/38936engrestrictedAccessTime to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) plus vemurafenib (V) in the phase Ill IMspire150 study.conferenceObjectCopyright AMER SOC CLINICAL ONCOLOGYOncology1527-7755